KR102760380B1 - 다가 및 다중특이적 dr5-결합 융합 단백질 - Google Patents

다가 및 다중특이적 dr5-결합 융합 단백질 Download PDF

Info

Publication number
KR102760380B1
KR102760380B1 KR1020187000975A KR20187000975A KR102760380B1 KR 102760380 B1 KR102760380 B1 KR 102760380B1 KR 1020187000975 A KR1020187000975 A KR 1020187000975A KR 20187000975 A KR20187000975 A KR 20187000975A KR 102760380 B1 KR102760380 B1 KR 102760380B1
Authority
KR
South Korea
Prior art keywords
gly
ser
ala
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187000975A
Other languages
English (en)
Korean (ko)
Other versions
KR20180030518A (ko
Inventor
존 씨. 티머
카일 에스. 존스
아미르 에스. 라자이
아브라힘 후세인
퀸 데브루
케이틀린 엠. 윌리스
브렌단 피. 에켈만
Original Assignee
인히브릭스 바이오사이언스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인히브릭스 바이오사이언스, 인크. filed Critical 인히브릭스 바이오사이언스, 인크.
Priority to KR1020257002277A priority Critical patent/KR20250017305A/ko
Publication of KR20180030518A publication Critical patent/KR20180030518A/ko
Application granted granted Critical
Publication of KR102760380B1 publication Critical patent/KR102760380B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001138—Tumor necrosis factors [TNF] or CD70
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020187000975A 2015-07-16 2016-07-18 다가 및 다중특이적 dr5-결합 융합 단백질 Active KR102760380B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257002277A KR20250017305A (ko) 2015-07-16 2016-07-18 다가 및 다중특이적 dr5-결합 융합 단백질

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562193309P 2015-07-16 2015-07-16
US62/193,309 2015-07-16
PCT/US2016/042862 WO2017011837A2 (en) 2015-07-16 2016-07-18 Multivalent and multispecific dr5-binding fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257002277A Division KR20250017305A (ko) 2015-07-16 2016-07-18 다가 및 다중특이적 dr5-결합 융합 단백질

Publications (2)

Publication Number Publication Date
KR20180030518A KR20180030518A (ko) 2018-03-23
KR102760380B1 true KR102760380B1 (ko) 2025-01-31

Family

ID=57757772

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257002277A Pending KR20250017305A (ko) 2015-07-16 2016-07-18 다가 및 다중특이적 dr5-결합 융합 단백질
KR1020187000975A Active KR102760380B1 (ko) 2015-07-16 2016-07-18 다가 및 다중특이적 dr5-결합 융합 단백질

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020257002277A Pending KR20250017305A (ko) 2015-07-16 2016-07-18 다가 및 다중특이적 dr5-결합 융합 단백질

Country Status (25)

Country Link
US (4) US10308720B2 (enExample)
EP (2) EP3322734B1 (enExample)
JP (4) JP6807606B2 (enExample)
KR (2) KR20250017305A (enExample)
CN (2) CN107922491B (enExample)
AU (2) AU2016291701B2 (enExample)
CA (1) CA2991634A1 (enExample)
CY (1) CY1123615T1 (enExample)
DK (1) DK3322734T3 (enExample)
ES (1) ES2833773T3 (enExample)
HR (1) HRP20201785T1 (enExample)
HU (1) HUE051896T2 (enExample)
IL (3) IL307994A (enExample)
LT (1) LT3322734T (enExample)
MX (2) MX2018000523A (enExample)
NZ (1) NZ777930A (enExample)
PL (1) PL3322734T3 (enExample)
PT (1) PT3322734T (enExample)
RS (1) RS61062B1 (enExample)
RU (2) RU2748620C2 (enExample)
SG (1) SG10201912410TA (enExample)
SI (1) SI3322734T1 (enExample)
SM (1) SMT202100066T1 (enExample)
WO (1) WO2017011837A2 (enExample)
ZA (1) ZA201800238B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL269826B1 (en) 2017-04-11 2025-09-01 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
WO2019129644A1 (en) * 2017-12-28 2019-07-04 Julius-Maximilians-Universität Würzburg TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FcγR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCγR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA)
CN110305210B (zh) * 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
JP7724061B2 (ja) 2018-04-11 2025-08-15 インヒブルクス バイオサイエンシズ インコーポレイテッド 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物ならびに関連する方法および使用
WO2020047705A1 (zh) * 2018-09-03 2020-03-12 安菲尼生命科技有限公司 Dr5单域抗体及其用途
GB201903767D0 (en) * 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
EP4041398A1 (en) * 2019-10-01 2022-08-17 Epsilogen Ltd Hybrid antibody
EP4154910A4 (en) * 2020-06-30 2024-09-11 Harbour Biomed (Shanghai) Co., Ltd Binding protein having h2l2 and hcab structures
EP4294842A1 (en) * 2021-02-19 2023-12-27 Inhibrx, Inc. Formulations of dr5 binding polypeptides
IL316085A (en) * 2022-04-08 2024-12-01 Inhibrx Biosciences Inc Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy
US20250302948A1 (en) * 2022-05-23 2025-10-02 Inhibrx Biosciences, Inc. DR5 Agonist and IAP Antagonist Combination Therapy
CN117285644A (zh) * 2022-06-16 2023-12-26 清华大学 一种相变调节元件及其用途
KR20250131767A (ko) 2022-09-28 2025-09-03 발린크 테라퓨틱스 리미티드 다가 단백질 및 스크리닝 방법
AU2024308381A1 (en) * 2023-06-29 2025-11-20 Odyssey Therapeutics, Inc. Anti-trailr2 antigen-binding proteins and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100460A (en) * 1990-12-20 1997-06-10 Ixsys Method for optimization of binding proteins and nucleic acids encoding a binding protein produced thereby
US20020147140A1 (en) * 2000-01-31 2002-10-10 Rosen Craig A. Nucleic acids, proteins, and antibodies
KR20070010046A (ko) 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
MX2007008017A (es) 2004-12-31 2007-09-12 Genentech Inc Polipeptidos que se ligan a br3 y usos de los mismos.
AU2006216683A1 (en) 2005-02-24 2006-08-31 Cemines, Inc. Compositions and methods for classifying biological samples
EP1937720B1 (en) 2005-08-18 2014-04-09 Ramot at Tel-Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
CA2632417A1 (en) 2005-12-06 2007-06-14 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
AU2007218045B2 (en) 2006-02-20 2011-11-10 Phylogica Limited Method of constructing and screening libraries of peptide structures
JP2008133206A (ja) 2006-11-28 2008-06-12 Yokohama City Univ 緑膿菌に対して感染防御能を誘導できる医薬組成物
EA201000903A1 (ru) 2007-11-30 2011-02-28 Калобиос Фармасьютикалс, Инк. Антитела к pcrv-антигену pseudomonas aeruginosa
SI2285408T1 (sl) * 2008-06-05 2019-02-28 Ablynx N.V. Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni
EP2328929A2 (en) * 2008-09-10 2011-06-08 Bac Ip B.V. Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
EP2408475B1 (en) 2009-03-18 2017-11-15 Wake Forest University Health Sciences Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa
WO2010115141A2 (en) 2009-04-02 2010-10-07 New York University System and uses for generating databases of protein secondary structures involved in inter-chain protein interactions
CN101717775B (zh) * 2009-11-13 2012-01-04 厦门大学 抗人死亡受体5的单链抗体基因
US8962807B2 (en) 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
US9120855B2 (en) * 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
EP2563816B1 (en) 2010-04-27 2014-11-12 National Research Council of Canada Anti-icam-1 single domain antibody and uses thereof
ES2617446T3 (es) * 2010-09-27 2017-06-19 Morphosys Ag Anticuerpo anti-cd38 y lenalidomida o bortezomib para el tratamiento del mieloma múltiple y nhl
CA2815888C (en) 2010-10-25 2020-06-30 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
CN103270047A (zh) 2010-12-23 2013-08-28 因特塞尔奥地利股份公司 Oprf/i剂及其在住院患者和其他患者中的用途
UA118833C2 (uk) * 2011-08-17 2019-03-25 Ґлаксо Ґруп Лімітед Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1
SMT202000091T1 (it) * 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
CA2854806A1 (en) 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
US9879093B2 (en) 2011-12-20 2018-01-30 Adaerata, Limited Partnershp Single domain antibodies as inhibitors of PCSK9
WO2013128031A1 (en) 2012-03-02 2013-09-06 Ablynx Nv Pseudomonas aeruginosa pcrv binding single variable domain antibodies
US20130302250A1 (en) 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
US20140161796A1 (en) 2012-09-13 2014-06-12 Andreas Loew Single chain proteins with c-terminal modifications
BR112015010240A2 (pt) 2012-11-06 2017-08-22 Medimmune Ltd Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas
CN102924600B (zh) * 2012-11-14 2013-10-30 河南大学 死亡受体5激动性多价抗体及其在制备抗肿瘤药物中的应用
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
US9862777B2 (en) 2013-05-28 2018-01-09 Vib Vzw Single domain antibodies against SOD1 and their use in medicine
KR20160103007A (ko) * 2014-01-10 2016-08-31 각코호진 데이쿄 헤이세이 다이가쿠 재조합 편성 혐기성 그램 양성균

Also Published As

Publication number Publication date
JP2023022214A (ja) 2023-02-14
US20240376220A1 (en) 2024-11-14
AU2016291701B2 (en) 2022-09-29
AU2016291701A1 (en) 2018-01-25
PT3322734T (pt) 2020-11-30
EP3322734A2 (en) 2018-05-23
ES2833773T3 (es) 2021-06-15
IL307994A (en) 2023-12-01
JP2025084923A (ja) 2025-06-03
MX2018000523A (es) 2018-04-13
US11976126B2 (en) 2024-05-07
CN114106178A (zh) 2022-03-01
KR20250017305A (ko) 2025-02-04
CA2991634A1 (en) 2017-01-19
MX2023002379A (es) 2023-03-21
CN107922491B (zh) 2021-09-28
HK1254433A1 (en) 2019-07-19
RU2018102803A3 (enExample) 2019-12-27
JP6807606B2 (ja) 2021-01-06
DK3322734T3 (da) 2020-10-26
US20220064318A1 (en) 2022-03-03
IL256772A (en) 2018-03-29
NZ777930A (en) 2025-05-02
PL3322734T3 (pl) 2021-05-04
RU2748620C2 (ru) 2021-05-28
HRP20201785T1 (hr) 2021-01-22
CN107922491A (zh) 2018-04-17
RU2021111382A (ru) 2021-05-21
KR20180030518A (ko) 2018-03-23
LT3322734T (lt) 2021-02-10
US11117973B2 (en) 2021-09-14
WO2017011837A2 (en) 2017-01-19
US20190309083A1 (en) 2019-10-10
ZA201800238B (en) 2021-07-28
EP3322734A4 (en) 2019-04-17
SMT202100066T1 (it) 2021-03-15
SG10201912410TA (en) 2020-02-27
SI3322734T1 (sl) 2021-02-26
US20170015753A1 (en) 2017-01-19
EP3322734B1 (en) 2020-09-09
HUE051896T2 (hu) 2021-03-29
US10308720B2 (en) 2019-06-04
JP2018522888A (ja) 2018-08-16
BR112018000584A2 (pt) 2018-09-11
IL292037A (en) 2022-06-01
WO2017011837A3 (en) 2017-03-02
JP7244938B2 (ja) 2023-03-23
RU2018102803A (ru) 2019-08-19
RS61062B1 (sr) 2020-12-31
AU2022291498A1 (en) 2023-02-02
EP3798232A1 (en) 2021-03-31
NZ738850A (en) 2024-11-29
CY1123615T1 (el) 2022-03-24
IL256772B (en) 2022-05-01
JP2021046414A (ja) 2021-03-25

Similar Documents

Publication Publication Date Title
JP7244938B2 (ja) 多価及び多重特異性ｄｒ５結合融合タンパク質
US20200347143A1 (en) Novel tnfr agonists and uses thereof
JP2018523493A (ja) 多価および多重特異性ｇｉｔｒ結合融合タンパク質
US20230159661A1 (en) T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
CA3194384A1 (en) Caninized rat antibodies to canine interleukin-31 receptor alpha
HK40048814A (en) Multivalent and multispecific dr5-binding fusion proteins
HK1254433B (en) Multivalent and multispecific dr5-binding fusion proteins
WO2025149633A1 (en) Bispecific antigen binding proteins
BR122025011160A2 (pt) Proteínas de fusão com ligação de dr5 multivalentes e multiespecíficas
BR112018000584B1 (pt) Polipeptídeo isolado que se liga pelo menos ao receptor de morte 5 (dr5) e seus usos

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180111

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20190129

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210712

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230921

Patent event code: PE09021S01D

PE0601 Decision on rejection of patent

Patent event date: 20240627

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

AMND Amendment
PX0901 Re-examination

Patent event code: PX09012R01I

Patent event date: 20240925

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20241106

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250121

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250122

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250122

End annual number: 3

Start annual number: 1

PG1601 Publication of registration